Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 10021,China
Abstract Objective To evaluate the short-term clinical efficacy and adverse events of volumetric modulated arc therapy (VMAT) in the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods From January to December 2016,58 patients (47 male and 11 female) with unresectable locally advanced NSCLC received concurrent or sequential chemoradiotherapy. The radiation dose was ranged from 38 Gy to 66 Gy. The radiation dose was equal or higher than 56 Gy in 53 patients (92%).The median radiotherapy fraction was 30,1.8 Gy to 3.0 Gy for each fraction. Twenty-eight patients (48%) received concurrent chemoradiotherapy. Results The median follow-up time was 9 months. The 1-year overall survival (OS) rate was 84% and the 1-year progression-free survival (PFS) rate was 48%.Eleven patients (19%) suffered from symptomatic radiation pneumonitis and one of them died of radiation pneumonitis. Within 6 months after radiotherapy,31 patients (53%) developed asymptomatic local pulmonary fibrosis on CT images. Seventeen patients (29%) suffered from grade Ⅱ esophagitis. Ten cases (17%) had ≥ grade Ⅲ adverse events and 9 of them presented with leucopenia. Conclusions VMAT yields high short-term clinical efficacy and tolerable adverse events in the treatment of locally advanced NSCLC,which does not increase the risk of pneumonitis.
Zhang Tao,Zhuo Zongmei,Xiao Zefen et al. Short-term clinical efficacy and adverse events of volumetric modulated arc therapy in patients with locally advanced non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(8): 729-733.
Zhang Tao,Zhuo Zongmei,Xiao Zefen et al. Short-term clinical efficacy and adverse events of volumetric modulated arc therapy in patients with locally advanced non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(8): 729-733.
[1] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338. [2] Aupérin A,Le Péchoux C,Rolland E,et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J].J Clin Oncol,2010,28(13),2181-2190.DOI:10.1200/JCO.2009.26.2543. [3] Otto K.Volumetric modulated arc therapy:IMRT in a single gantry arc[J].Med Phys,2008,35(1):310-317.DOI:10.1118/1.2818738. [4] Xu Y,Deng W,Yang S,et al. Dosimetric comparison of the helical tomotherapy,volumetric-modulated arc therapy and fixed-field intensity-modulated radiotherapy for stage ⅡB-ⅢB non-small cell lung cancer[J].Sci Rep,2017,7(1):14863.DOI:10.1038/s41598-017-14629-w. [5] Scorsetti M,Navarria P,Mancosu P,et al. Large volume unresectable locally advanced non-small cell lung cancer:acute toxicity and initial outcome results with rapid arc[J].Radiat Oncol,2010,5:94.DOI:10.1186/1748-717X-5-94. [6] Scorsetti M,Navarria P,De Rose F,et al. Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy[J].J Cancer Res Clin Oncol,2014,140(11):1937-1945.DOI:10.1007/s00432-014-1739-7. [7] 任骅,金晶,肖琴,等.直肠癌术前IMRT同期化疗与VMAT同期化疗的急性不良反应比较[J].中华放射肿瘤学杂志,2014,23(3):205-209.DOI:10.3760/cma.j.issn.1004-4221.2014.03.007. Ren H,Jin J,Xiao Q,et al. Comparison of acute toxicities between IMRT and VMAT in preoperative concurrent chemoradiotherapy for rectal cancer[J].Chin J Radiat Oncol,2014,23(3):205-209.DOI:10.3760/cma.j.issn.1004-4221.2014.03.007. [8] 刘丽虹,王澜,韩春,等.食管癌VMAT与IMRT的剂量学比较[J].中华放射肿瘤学杂志,2015,24(3):318-322.DOI:10.3760/cma.j.issn.1004-4221.2015.03.022. Liu LH,Wang L,Han C,et al. The application of volumetric modulated arc therapy in esophageal carcinoma[J].Chin J Radiat Oncol,2015,24(3):318-322.DOI:10.3760/cma.j.issn.1004-4221.2015.03.022. [9] 高瀚,贾鹏飞,陈炳森,等.食管癌VMAT与IMRT剂量比较的Meta分析[J].中华放射肿瘤学杂志,2017,26(9):1055-1061.DOI:10.3760/cma.j.issn.1004-4221.2017.09.015. Gao H,Jia PF,Chen BS,et al. Dosimetric comparison between volumetric-modulated arc therapy and intensity-modulated radiotherapy for esophageal cancer:a meta-analysis[J].Chin J Radiat Oncol,2017,26(9):1055-1061.DOI:10.3760/cma.j.issn.1004-4221.2017.09.015. [10] McGrath SD,Matuszak MM,Yan D,et al. Volumetric modulated arc therapy for delivery of hypofractionated stereotactic lung radiotherapy:a dosimetric and treatment efficiency analysis[J].Radiother Oncol,2010,95(2):153-157.DOI:10.1016/j.radonc.2009.12.039. [11] Navarria P,Ascolese AM,Mancosu P,et al. Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC)[J].Radiother Oncol,2013,107(3):414-418.DOI:10.1016/j.radonc.2013.04.016. [12] Ong CL,Verbakel WF,Cuijpers JP,et al. Stereotactic radiotherapy for peripheral lung tumors:a comparison of volumetric modulated arc therapy with 3 other delivery techniques[J].Radiother Oncol,2010,97(3):437-442.DOI:10.1016/j.radonc.2010.09.027. [13] Yamashita H,Haga A,Takahashi W,et al. Volumetric modulated arc therapy for lung stereotactic radiation therapy can achieve high local control rates[J].Radiat Oncol,2014,9:243.DOI:10.1186/s13014-014-0243-1. [14] Scorsetti M,Navarria P,De Rose F,et al. Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy[J].J Cancer Res Clin Oncol,2014,140(11):1937-1945.DOI:10.1007/s00432-014-1739-7. [15] Liu L,Bi N,Ji Z,et al. Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy—retrospective analysis of 203 cases[J].BMC Cancer,2015,15:715.DOI:10.1186/s12885-015-1710-2. [16] Palma DA,Senan S,Tsujino K,et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer:an international individual patient data meta-analysis[J].Int J Radiat Oncol Biol Phys,2013,85(2):444-450.DOI:10.1016/j.ijrobp.2012.04.043.
2018, Vol. 27 
